為因應政府領導發展前瞻生物科技政策，積極鼓勵新一代研發及新創人才在生物科技新領域的培育工作，本團隊由交大、陽明/北榮、高醫跨領域 (生物、資訊、材料、化學、物理) 專家及臨床醫師群所組成，已有多年的合作經驗，並與多所國際頂尖大學UCSD、Johns Hopkins U.、UCLA、Harvard U.及U. Ottawa等長期合作，擁有許多基礎研究與藥物開發關鍵技術，且研究表現與產業化應用成果相當突出。
由國立交通大學籌組”智慧型藥物與智能生物裝置研究中心 (Center for Intelligent Drug Systems and Smart Bio-devices, IDS2B)”，針對肝癌、乳癌、腎臟病、與神經性退化疾病等三大類臨床病變，提供
Center for Intelligent Drug Systems and Smart Bio-devices-IDS2B
Advances in medical technology and cultivate talents for biomedical research/development and industry innovation are the key issues of the Biomedical Industry Innovation program of our government.
To achieve these goals, a cross-disciplinary international team, with world-renown experts in Biology, Bio-Informatics, Materials Science, Chemistry and Physics, together with Clinic Physicians, across the universities included National Chiao Tung University (NCTU), National Yang Ming University (NYMU), Taipei Veterans General Hospital (TVGH), Kaohsiung Medical University (KMU), UCSD, Johns Hopkins U., UCLA, Harvard U. and U. Ottawa are organizing to form "“Center for Intelligent Drug Systems and Smart Bio-devices, IDS2B” at NCTU.
The main goals of IDS2B are focusing on developing synergistic multi-biomarker-driven intelligent drugs to target liver and breast cancers, the two most-concerned oncological challenges in Taiwan, on one hand, and on the other hand, to explore niche technologies in building novel functionalized micro-kidney and bio-electronic retinal prosthesis, via a newly-evolved 3D bioprinted technology to be built up in NCTU. Pathological tissue bank (from patients) associated with gene sequencing and drug computation fundamentals will be setup as a foundation to find optimal answers for the two niche topics aforementioned, which are of prime healthcare issues in Taiwan and worldwide as well. Meanwhile, a strong connection with clinical rehabilitation team from TVGH ensures optimized performance from resulting research outcomes.
Besides technical parts, the research team members have well-experienced patenting and technique transferring reputation, reaching top licensing loyalty in Taiwan in recent 5 years, and will surely proceed with further expansion of the task forces in IDS2B .
In short, the prime goals of IDS2B will be specializing onto the development of
(1) precision earlier diagnostics/ personalize medicine;
(2) intelligent drugs and associated multfunctional drug delivery nanosystems;
(3) smart implantable platform, with 3D bioprinted functionalized organs and
(4) genome editing devices to provide synergistic solutions to against liver and breast cancers, kidney diseases, and neural degenerative diseases.
Establishing an entrepreneurship outlet with start-up bio-ventures for those matured biotechnologies will be equally considered as one of the ultimate destinations of the IDS2B.